b-cells ex2

Development of B Lymphocytes

1. B-cell Populations

  • B cells can be categorized into various subtypes:

    • B-1 B cells:

    • Occupy and safeguard body cavities.

    • B-2 B cells:

    • Represent the majority of B cells that recognize and combat infections upon activation in secondary lymphoid tissues.

    • Marginal-zone B cells:

    • Located in the spleen, they are responsible for protecting against bloodborne pathogens.

2. Fetal B-cell Development

A. Development Locations and Mechanism

  • B-cell development primarily occurs in:

    • Bone marrow

    • Spleen (post-birth)

  • The early embryo lacks bone marrow, resulting in changes in B-cell developmental locations depending on where hematopoietic stem cell (HSC) production occurs.

B. Anatomical Changes Over Development

  • Hematopoiesis initiation occurs in:

    • Yolk sac

  • Later fetuses display hematopoietic stem cells in these locations:

    • Aorta-gonad-mesonephros (AGM)

    • Fetal liver

    • Placenta (until day 40)

C. Timing of Key Events

  • Production of precursor B cells (pre-B cells) begins in the fetal liver after approximately 40 days of gestation.

  • Bone marrow hematopoiesis initiates around day 75, with the liver still serving as a major B-cell developmental site.

D. B-cell Development in the Fetal Liver

  • Fetal HSCs continually divide, unlike adult bone marrow HSCs that need activation signals to proliferate.

  • The primary B cell subset during fetal liver development consists of B-1 B cells, crucial in countering gut and lung pathogens.

E. Characteristics of B-1 B Cells

  • Produce cross-reactive antibodies for diverse microbes through common carbohydrates.

  • Exhibit low expression of terminal deoxynucleotidyl transferase (TdT).

  • V(D)J recombinase operates using a limited subset of V, D, and J segments.

F. Transition to Bone Marrow Development

  • As fetal development progresses, B-cell development shifts from the liver to bone marrow, primarily transitioning into B-2 B cells.

  • B-1 B cells maintain self-renewal in pleural and peritoneal cavities.

3. Hematopoietic Stem Cells (HSCs) in Bone Marrow

A. HSC Characteristics

  • HSCs are multipotent and self-renewing; distinguished from other cells by:

    • Less-organized chromatin structure and nucleosome packing.

    • Specific acetylation and methylation patterns on histone proteins driving gene transcription.

  • HSCs activate genes crucial for transitioning from stem cells to common lymphoid progenitor cells via transcription factors.

B. Interaction with Stromal Cells

  • HSCs interact with stromal cells through the c-Kit molecule, binding to stem cell factors, which:

    • Maintains contact between HSCs and stromal cells.

    • Facilitates differentiation into multipotent progenitor cells.

C. Multipotent Progenitor Cells

  • Once HSCs differentiate, they lose self-renewal capacity and begin expressing:

    • CD34 (a detectable cell-surface receptor)

    • CXCR4 (interacts with the chemokine CXCL12 from stromal cells).

  • They eventually evolve into lymphoid-primed multipotent progenitor cells.

D. Lymphoid-Primed Multipotent Progenitor Cells

  • Express fms-related tyrosine kinase 3 receptor (flt-3), which binds to bone marrow stromal cell ligands, prompting the expression of IL-7 receptors critical for B-cell differentiation during early developmental stages.

  • At this stage, they begin expressing RAG1, RAG2, and TdT.

E. Early Lymphoid Progenitor Cells

  • Major components of V(D)J recombinase are present, destined to become lymphocytes.

  • Progenitor cells differentiate into B cells if they remain in bone marrow or T cells if they migrate to the thymus.

F. Common Lymphoid Progenitor Cells

  • Capable of differentiating into:

    • NK cells

    • Innate lymphoid cells

    • B and T cells.

  • Cells binding IL-7 progress towards B-cell development through chromatin remodeling and accessibility to immunoglobulin genes.

4. B-cell Development in Adults

A. Location & Process

  • Bone marrow serves as the primary site for B-cell development and hematopoiesis.

  • Specialized cell interactions within the bone marrow are essential for B-cell differentiation.

  • Development initiates in bone marrow and completes in the spleen.

B. Stages of Development in Bone Marrow

  1. Early pro-B cells

  2. Pro-B cells

  3. Pre-B cells

  4. Immature B cells

C. B-cell Maturation in the Spleen

  • Transitional B cells migrate from the bone marrow to the spleen, which functions both as a filter and site for lymphocyte expansion and selection.

D. Selection of Transitional B Cells

  • Transitional B cells undergo:

    • T1 transitional stage (characterized by high IgM and low IgD levels).

    • T2 transitional stage (characterized by increased IgD, CD21, and CD23 expression).

    • Apoptosis of self-reactive T1 B cells, survival signals enable T2 cells to transition into mature B cells.

5. Critical Checkpoints in B-cell Development

A. Process of Checkpoints

  • B cells can only produce one immunoglobulin type.

  • Major checkpoints in B-cell development include:

    • Heavy chain checkpoint

    • Light chain checkpoint

B. Formation of Pro-B Cells

  • In early pro-B cells, heavy chain locus rearrangement occurs, involving RAG1 and RAG2.

  • Successful heavy chain recombination leads to the formation of a pre-B-cell receptor and the progression to pre-B cells.

C. Allelic Exclusion in B-cell Development

  • Ensures that only one heavy chain is expressed, leading to functional immunoglobulin through RAG1 and RAG2 inactivation after successful formation of a pre-B-cell receptor.

  • Cells that can't produce functional heavy chains face apoptosis.

6. Development of Immature B Cells

A. Formation from Pre-B Cells

  • Light chain loci undergo recombination in small pre-B cells involving both λ and κ loci until functional light chains are achieved, continuing until unsuccessful attempts lead to cell apoptosis.

B. Action of Immature B Cells

  • Immature B cells express antibodies on their surface and can be tested for self-reactivity as they mature in the bone marrow.

7. Negative Selection of B Cells

A. Mechanism of Negative Selection

  • Post-self-reactivity testing leads to:

    • Clonal deletion (removal of self-reactive B cells through apoptosis).

    • Receptor editing (reactivation of rearrangement at the light chain locus).

    • Anergy (self-reactive B cells not deleted may exist in a non-responsive state).

B. Stringency of Negative Selection

  • B cells are less stringently selected than T cells due to different activation pathways, often requiring help from T cells for activation.

8. Positive and Negative Selection in the Spleen

A. B-cell Maturation Process in the Spleen

  • Immature B cells undergo maturation with 75% migrating to the spleen where they transition between T1 and T2 stages, respectively.

  • T1 B cells undergoing negative selection are removed if they are self-reactive; T2 B cells survive and further mature into B cells.

9. Activation of Mature B Cells

A. Transition to Circulation

  • Once mature, B cells exit the spleen and enter circulation as naive B cells.

  • They assess for specific antigens in lymph nodes via high endothelial venules (HEVs).

B. Activation and Proliferation of B Cells

  • Upon recognizing an antigen, B cells proceed with activation and cloning.

  • If no antigen recognition occurs, they migrate to other lymphoid tissues.

10. Development of B-1 and Marginal-Zone B Cells

A. Locations and Characteristics of B-1 Cells

  • B-1 B cells inhabit the pleural and peritoneal cavities, showcasing limited immunoglobulin diversity and requiring a different developmental environment than B-2 cells.

B. Marginal-Zone B Cells

  • Located in the marginal zone of the spleen, these B cells specialize in recognizing bloodborne pathogens.

C. Developmental Signals

  • Both B-1 and marginal-zone B cell development is influenced by self-antigen recognition and Notch signaling.

11. Mucosal Immunity

A. Overview of Mucosal Surfaces

  • Mucosa: thin tissue secreting mucus, lines various body tracts, and serves as a barrier to pathogens while playing roles in nutrient absorption and reproduction.

B. Systemic vs. Mucosal Immune Response

  • Systemic response involves inflammation, while mucosal response promotes barrier maintenance and is less inflammatory.

C. Mucus Functionality

  • Mucus functions as a protective layer, lubricating surfaces while preventing pathogen colonization.

  • Mucins in mucus provide viscosity, trapping pathogens and facilitating immune responses.

12. Mucosa-associated Lymphoid Tissue (MALT)

A. MALT Overview

  • MALT centralizes adaptive immune activation at mucosal surfaces.

  • Comprises various types according to region (GALT for gut, BALT for bronchial, etc.).

B. Gut-associated Lymphoid Tissue (GALT)

  • Contains immune effector cells within connective tissues near mucosal epithelia.

  • Structures like Peyer’s patches and isolated lymphoid follicles play vital roles in immune response.

C. Role of Microbiota in Gut Immunity

  • Compete with pathogens for space and nutrients, producing antimicrobial agents and preventing harmful colonization.

D. Immune System Distinction

  • Mucosal immune responses maintain a balance, distinguishing beneficial microorganisms amidst potential pathogens through limited interactions and specialized immune responses.

E. Antigen Sampling via M Cells

  • M cells transport antigens to MALT, facilitating immune cell activation and response initiation.

F. Dendritic Cells in MALT

  • Dendritic cells capture antigens, relocating to MALT for effective antigen presentation, critical for T-cell activation.

13. Innate and Adaptive Immunity in Mucosal Protection

A. Innate Immune Response

  • Efforts involve intestinal macrophages, gut dendritic cells, and innate lymphoid cells (ILC).

  • These immune components maintain a delicate balance to remove pathogens while minimizing inflammation.

B. Migration of Effector Lymphocytes

  • Activated CD4 helper T cells and B cells migrate to MALT and contain mechanisms for recognizing and combating pathogens directly.

C. Antibody Response by Plasma Cells

  • Plasma cells are abundant in mucosal tissues, particularly secreting IgA, vital for neutralizing pathogens at mucosal surfaces.

D. Involvement of TH2 Cells

  • IL-5 and IL-13 from activated T cells target helminth infections, orchestrating responses that limit inflammation while promoting pathogen expulsion.

14. Allergies and Hypersensitivity

A. Definition and Mechanisms

  • Hypersensitivity occurs when immune responses are inappropriately activated by harmless antigens, leading to various allergic reactions.

B. Types of Hypersensitivity Reactions

  1. Type I: IgE-mediated reactions leading to mast cell activation.

  2. Type II: IgG-mediated destruction of self-cells.

  3. Type III: Immune complexes leading to inflammation.

  4. Type IV: Delayed T-cell-mediated reactions.

C. Inflammatory Mediators in Allergies

  • Allergic reactions involve mediators such as histamine and prostaglandins, which dictate the symptoms experienced during hypersensitivity responses.

D. Mechanism of Type I Hypersensitivity

  • Type I allergies involve mast cells and basophils that bind IgE and release pro-inflammatory mediators following allergen exposure.

E. Clinical Presentation of Allergies

  • Common manifestations include rhinitis, asthma, and anaphylaxis. Consulting healthcare for correct testings, such as skin prick tests, assists in diagnosing allergies effectively.

F. Prevention and Treatment of Allergies

  • Treatment options encompass corticosteroids for inflammation control and immunotherapy to promote tolerance to allergens.